![Nick Glover](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nick Glover
Directeur/Membre du Conseil chez
LITE STRATEGY, INC.
Fortune : - $ au 31/05/2026
Profil
Nicholas R.
Glover is Chief Executive Officer at MycRx Holdings, Inc. and MycRX, Independent Non-Executive Director at Lite Strategy, Inc. since 2013, and Director at Pattern Pharma, Inc. Former roles include President, Chief Executive Officer & Director at YM BioSciences, Inc. from 2012 to 2013, President, Chief Executive Officer & Director at Viventia Biotech, Inc. from 2000 to 2008, President, Chief Executive Officer & Director at Sierra Oncology, Inc. from 2014 to 2020, Chief Executive Officer at ProNAi Therapeutics, Inc., Investment Manager at Lumira Capital Investment Management, Inc., and Investment Analyst at University Medical Discoveries, Inc. Education includes graduate studies at the University of British Columbia, a doctorate from Simon Fraser University, and undergraduate studies at the University of East Anglia.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
LITE STRATEGY INC -.--% | 15/12/2025 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Nick Glover
| Sociétés | Poste | Début |
|---|---|---|
| LITE STRATEGY, INC. | Directeur/Membre du Conseil | 11/06/2013 |
Pattern Pharma, Inc.
 Pattern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical industry | Directeur/Membre du Conseil | - |
MycRx
 MycRx Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops small molecule inhibitors of the Myc oncoprotein | Directeur Général | 01/01/2020 |
Anciens postes connus de Nick Glover
| Sociétés | Poste | Fin |
|---|---|---|
| SIERRA ONCOLOGY, INC. | Directeur Général | 22/05/2020 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Produces cancer-related drug products | Directeur Général | 01/02/2013 |
University Medical Discoveries, Inc.
 University Medical Discoveries, Inc. Investment ManagersFinance UMDI focuses on seed and early-stage investments in the medical and life sciences. They help develop and commercialize research done by entrepreneurs and scientists at Canadian universities, hospitals and research institutes. The CIHR, MDS, and MedTech Partners Inc have also joined forces to launch the University Medical Discoveries Fund (UMDF). The CMDF is considered a partner of the UMDF. The UMDF’s “focus is to help develop and commercialize early-stage biomedical innovations” at Canadian universities and since 1996 it has invested in 31 early stage companies. This relationship between the CIHR and CMDF goes further. | Analyste en capital-investissement | 31/03/2009 |
Viventia Biotech, Inc.
 Viventia Biotech, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and commercializes monoclonal antibody products | Directeur Général | 01/06/2008 |
ProNAi Therapeutics Inc
 ProNAi Therapeutics Inc BiotechnologyHealth Technology Operates as a biopharmaceutical drug development company that develops nucleic-acid drugs | Directeur Général | - |
Formation de Nick Glover
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
50
Relations au 1er degré
12
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 12 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Produces cancer-related drug products | Health Technology |
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and commercializes monoclonal antibody products | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Develops novel therapeutic approaches for cancer and other diseases | Health Technology |
Lumira Capital Investment Management, Inc.
 Lumira Capital Investment Management, Inc. Investment ManagersFinance LUMIRA invests in revenue stage companies that are both privately held and publically traded companies located in the Canada and the United States. The firm focuses on sectors of therapeutic products and medical devices. It participates in the early stage capital financing. | Finance |
MEI Pharma, Inc.
 MEI Pharma, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products | Health Technology |
University of British Columbia
 University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Simon Fraser University
 Simon Fraser University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of East Anglia
 University of East Anglia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University Medical Discoveries, Inc.
University Medical Discoveries, Inc. Investment ManagersFinance UMDI focuses on seed and early-stage investments in the medical and life sciences. They help develop and commercialize research done by entrepreneurs and scientists at Canadian universities, hospitals and research institutes. The CIHR, MDS, and MedTech Partners Inc have also joined forces to launch the University Medical Discoveries Fund (UMDF). The CMDF is considered a partner of the UMDF. The UMDF’s “focus is to help develop and commercialize early-stage biomedical innovations” at Canadian universities and since 1996 it has invested in 31 early stage companies. This relationship between the CIHR and CMDF goes further. | Finance |
Pattern Pharma, Inc.
Pattern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical industry | Health Technology |
MycRx
MycRx Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops small molecule inhibitors of the Myc oncoprotein | Commercial Services |
ProNAi Therapeutics Inc
ProNAi Therapeutics Inc BiotechnologyHealth Technology Operates as a biopharmaceutical drug development company that develops nucleic-acid drugs | Health Technology |
